This course is an intensive course designed to provide an exploration of pharmacogenomics, the study of how genetic variations influence individual responses to drugs. This course provides a comprehensive understanding of the principles and methodologies used to identify genetic variants that affect drug metabolism, efficacy, and toxicity. In addition, this course emphasizes the application of this knowledge to develop personalized therapeutic strategies aimed at optimizing drug efficacy and minimizing adverse effects.
Key topics include the molecular basis of pharmacogenomics, techniques for genetic analysis, the role of genetic polymorphisms in drug response, and case studies illustrating applications of pharmacogenomic testing in clinical settings. In addition, the ethical, legal, and social implications of integrating pharmacogenomics into healthcare will be explored.
Learning outcomes
By the end of this course, participants will be able to:
- Understand Fundamental Concepts: يescribe the basic principles of pharmacogenomics, including the genetic mechanisms that influence drug metabolism, efficacy, and toxicity.
- Analyze Genetic Variants: identify and interpret common genetic variants that impact drug response using genomic data.
- Apply Pharmacogenomic Knowledge: develop personalized therapeutic strategies based on individual genetic profiles to optimize drug efficacy and minimize adverse effects.
- Explore Ethical and Legal Issues: Discuss the ethical, legal, and social implications of pharmacogenomics, including patient privacy, informed consent, and equitable access to genomic medicine.
Instructor information
- Dr. Yazan Jarrar.
- Associate Professor of Pharmacology.
- Department of Basic Medical Sciences, Collage of Medicine, Al-Balqa Applied University.
Certification
Upon completion of this course, a certificate of attendance approved by the Higher Health Council will be provided.
- Format In-Person Course
- Category Genetics
- Students 40
- Start 19 October 2024
- End 26 October 2024
- Registration End 18 October 2024